Hypervision Surgical is proud to announce that we have been awarded the 2025 Lippmann Award, a global distinction recognising impactful innovation in hyperspectral imaging. The award was presented at the IEEE WHISPERS Conference in Barcelona (12–14 November), where our CEO & Co-Founder Michael Ebner delivered a keynote on the future of real-time spectral imaging in surgery.
Michael Ebner, CEO & Co-Founder of Hypervision Surgical, alongside Philippe Monnoyer (left), Founder of the Lippmann Award, and Wouter Charle (right), Portfolio Manager at imec.
Recognising Breakthrough Contributions to Spectral Imaging
The Lippmann Award — named after Nobel Laureate Gabriel Lippmann — honours visionary companies that demonstrate exceptional innovation and real-world impact in spectral imaging. Winners are selected based on contributions over the past year that advance the state of the art, demonstrate real-world applicability, and strengthen the broader industrial and scientific community.
This recognition reflects Hypervision’s progress in translating hyperspectral imaging from research settings into high-stakes clinical environments.
A Year of Transformative Progress
Over the past 12 months, Hypervision has achieved major milestones in its mission to redefine surgical intelligence through spectral imaging.
Regulatory Breakthroughs:
In 2025, Hypervision became the first company globally to receive U.S. FDA clearance for real-time spectral imaging in surgery, including acceptance into the FDA Safer Technologies Program (STeP) and issuance of a dedicated product code for our novel AI/ML-based approach. Our platform delivers dye-free, real-time tissue oxygenation, providing pixel-level physiological insights at the point of care.
Clinical Deployment:
Hypervision’s platform has already been used in over 150 procedures in UK operating rooms with a particular focus on general surgery applications. Early clinical experience demonstrates strong potential for intraoperative assessment of bowel viability, with the aim of reducing complications such as anastomotic leaks in colorectal surgery — a major source of postoperative morbidity in colorectal surgery.
Technology Built for Scale:
Hypervision’s AI platform brings ultra-compact spectral sensing to surgical vision systems, enabling real-time spectral imaging at 60+ frames per second and high-fidelity, pixel-level tissue characterisation previously unattainable in the operating room.
Strengthened by Strategic Partnership:
Our strategic venture partnership with imec, a world-leading nanoelectronics innovation hub, is accelerating the development of scalable on-chip spectral sensing paired with surgery-certified real-time AI analytics, advancing the next generation of surgical hyperspectral imaging.
Hypervision’s receipt of the Lippmann Award underscores not only our technological leadership but also the real-world momentum behind our mission to bring spectral imaging into everyday surgical practice.
As we continue to expand deployment, evolve our AI capabilities, and deepen clinical integration, we remain committed to building a future where spectral imaging and intelligent analytics elevate surgical precision worldwide.